DUBLIN, Sept. 16, 2022 /PRNewswire/ -- The "Monoclonal Antibodies for Oncology: Global Markets" report has been added to
ResearchAndMarkets.com's offering.
The current report provides detailed exposure of global monoclonal antibodies for the oncology market.
This report highlights the current and future market potential of monoclonal antibodies for oncology treatment and includes a detailed analysis of the market's drivers, challenges, and opportunities.
The report also covers market projections to 2027 and market share for key market players. The report details the market share of monoclonal antibodies for oncology based on type and application.
The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides the impact of the COVID-19 pandemic on this market.
Company profiles of major players, including AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc, Pfizer Inc.
Report Includes
25 data tables and 24 additional tables
A brief general outlook of the global monoclonal antibodies for oncology market
Analyses of the global market trends, with market revenue (sales data) for 2020 and 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
Highlights of the current and future market potential of monoclonal antibodies for oncology treatment, and areas of focus to forecast this market into various segments and sub-segments
Evaluation of the actual market size for monoclonal antibodies in oncology treatment, forecasted growth trends, and corresponding market share analysis by type of antibody, application area, and region
Technology assessment of the key drivers, restraints and opportunities that will shape the market over the next five years (2022 to 2027)
In-depth information on increasing investments on R&D activities, key technology issues, industry specific challenges, major types of end-user markets, and COVID-19 implications on the progress of this market
Review of the patent landscape and new developments in the market for monoclonal antibodies for oncology and associated clinical trials
Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues
Key Topics Covered:
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing this Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Custom Research
Related Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Monoclonal Antibodies
History of Monoclonal Antibodies
Advantages and Disadvantages of Monoclonal Antibodies
Monoclonal Antibodies in Oncology
Types of Monoclonal Antibodies
Chapter 4 Market Dynamics
Market Drivers
Increasing Incidence of Cancer
New Product Launches
Rising Healthcare Expenditures and Government Funding
Licensing and Collaboration Agreements
Market Barriers
Price Controls
Regulatory Approval Pressures
Entry of Biosimilars
Opportunities
Impact of Covid-19
Chapter 5 Market Breakdown by Type
Types of Monoclonal Antibodies for Oncology
Market Overview
Market Revenue
Global Market for Monoclonal Antibodies in Oncology by Type
Humanized Monoclonal Antibodies
Human Monoclonal Antibodies
Chimeric Monoclonal Antibodies
Chapter 6 Market Breakdown by Application
Overview
Lung Cancer
Breast Cancer
Colorectal Cancer
Blood Cancer
Chapter 7 Market Breakdown by Region
Introduction
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
India
Japan
Rest of Asia-Pacific
Rest of the World
Market Size and Forecast
Chapter 8 Regulatory Aspects
New Approvals of Monoclonal Antibodies for Oncology
Recalls, Withdrawals, and Safety Alerts
Chapter 9 Patent Review/ New Developments
New Developments
Phase I Clinical Trials
Phase Ii Clinical Trials
Phase Iii Clinical Trials
Chapter 10 Competitive Landscape
Mergers, Acquisitions, and Collaborations
Company Market Shares
Chapter 11 Company Profiles
Amgen Inc.
Astrazeneca Pharmaceuticals
Bristol-Myers Squibb
Eli Lilly
F. Hoffmann-La Roche AG
GlaxoSmithKline
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Merck Kgaa
Pfizer Inc.
Sanofi S.A.
Seagen
For more information about this report visit
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo:
SOURCE Research and Markets